Leuprolide mesylate SR is under clinical development by Foresee Pharmaceuticals and currently in Phase III for Central Precocious Puberty. According to GlobalData, Phase III drugs for Central Precocious Puberty does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Leuprolide mesylate SR LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Leuprolide mesylate SR overview

Leuprolide mesylate (Camcevi) is a synthetic peptide analogue of gonadotropin-releasing hormone (GnRH). It is formulated as sustained release emulsion and suspension for subcutaneous route of administration. Camcevi is indicated for the treatment of adult patients with advanced prostate cancer. Camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

FP-001 (Leuprolide mesylate) is under development for the treatment of prostate cancer and HER2 negative primary breast cancer, central precocious puberty. The therapeutic candidate is a synthetic peptide administered through subcutaneous and parenteral route. It is a sustained release formulation delivered through a depot system. It acts by targeting gonadotropin-releasing hormone receptor. It developed based on stabilized injectable formulation (SIF) platform technology.

Foresee Pharmaceuticals overview

Foresee Pharmaceuticals (FP) is a clinical-stage pharmaceutical company. It focuses on developing drugs for unmet medical needs. The company’s product portfolio comprises FP-001, for prostate cancer, FP-025, for asthma and chronic obstructive pulmonary disease, FP-020, for Alport syndrome and FP-014, for prostate cancer among others. It harnesses the stabilized injectable formulation (SIF) platform technology to develop controlled release drug delivery systems for peptides, small molecules and proteins. The company works in collaboration with ScinoPharm and Pierre Fabre to research and develop its product portfolio. It has an operational presence in Taiwan and the US. FP is headquartered in Taipei, Taiwan.

For a complete picture of Leuprolide mesylate SR’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.